SUMMIT, N.J., July 24, 2026x
Tylenol®, a flagship pain relief brand from Kenvue, has received U.S. Food and Drug Administration (FDA) approval for Tylenol® with Naproxen, the first and only over-the-counter (OTC) fixed-dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg). The newly approved product represents a significant advancement in non-opioid pain management, combining the rapid onset of acetaminophen with the extended anti-inflammatory effects of naproxen sodium in a single dose. Designed to begin relieving pain in under 30 minutes while delivering up to 12 hours of pain relief, the innovative formulation addresses an important unmet need for patients seeking long-lasting OTC pain control without relying on opioids. The FDA approval also grants Kenvue a three-year exclusivity period for the novel OTC fixed-dose combination, reinforcing the product’s innovative profile and expanding treatment options for millions of individuals managing persistent pain.
FDA Approval Expands Non-Opioid Pain Relief Options
The approval of Tylenol® with Naproxen introduces a new approach to over-the-counter pain management by combining two well-established non-opioid analgesics into a single fixed-dose product. The formulation integrates 650 mg of acetaminophen, known for its fast pain-relieving properties, with 220 mg of naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID) recognized for its prolonged analgesic effects. This dual mechanism enables patients to receive both rapid pain relief and sustained symptom control without coordinating multiple OTC medications or staggered dosing schedules. According to Kenvue, consumer research indicates that 75% of individuals experiencing persistent pain remain dissatisfied with currently available pain relief options, highlighting the need for simplified and more effective treatment strategies. By eliminating the complexity of combining separate OTC products, the new therapy offers a convenient, clinically validated alternative that may improve patient adherence while reducing reliance on prescription opioid medications.
Clinical Studies Demonstrate Superior Pain Relief
The FDA approval is supported by a comprehensive clinical development program consisting of eight clinical studies, which demonstrated that the fixed-dose combination consistently delivered superior pain relief compared with either acetaminophen alone or naproxen sodium alone. Clinical data showed that the product begins providing relief in less than 30 minutes and maintains pain control for up to 12 hours following a single dose. Researchers designed the clinical program to determine whether combining two proven analgesics into one standardized OTC formulation could provide enhanced efficacy while maintaining the well-established safety profiles of both active ingredients. The findings suggest that patients no longer need to independently combine separate pain medications to achieve multimodal pain control. Additional scientific data from the development program will be presented at PAINWeek 2026, providing healthcare professionals with further evidence supporting the product’s clinical performance across multiple pain models.
Advertisement
Innovation Reinforces Tylenol’s Longstanding Leadership
The launch of Tylenol® with Naproxen builds upon more than 70 years of innovation in pain management and reflects Kenvue’s continued commitment to expanding accessible, evidence-based OTC therapeutic solutions. Throughout its history, the Tylenol brand has introduced several milestone products, including children’s liquid acetaminophen formulations and higher-dose OTC pain relief options that helped establish new standards in non-prescription pain care. With the addition of the first FDA-approved OTC fixed-dose combination of acetaminophen and naproxen sodium, Kenvue further strengthens its leadership in non-opioid pain management while addressing the growing demand for safer, convenient alternatives to prescription therapies. As healthcare providers continue seeking effective strategies to reduce opioid exposure and improve long-term pain management, this approval represents an important advancement in consumer healthcare by providing a scientifically validated, accessible solution that combines fast onset, extended pain relief, and simplified dosing within a single over-the-counter medicine.
Source: Kenvue press release
